Literature DB >> 8794289

Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor protein.

M A Egan1, L M Carruth, J F Rowell, X Yu, R F Siliciano.   

Abstract

The mechanisms involved in the incorporation of viral glycoproteins into virions are incompletely understood. For retroviruses, incorporation may involve interactions between the Gag proteins of these viruses and the cytoplasmic domains of the relevant envelope (Env) glycoproteins. Recent studies have identified within the cytoplasmic tail of the human immunodeficiency virus type 1 (HIV-1) Env protein a tyrosine-containing internalization motif similar to those found in the cytoplasmic domains of certain cell surface proteins that undergo rapid constitutive endocytosis in clathrin-coated pits. Given that surface expression of the HIV-1 Env protein is essential for the production of infectious virus, the presence of this internalization motif is surprising. We show here that in contrast to the rapid rate of Env protein internalization observed in cells expressing the Env protein in the absence of other HIV-1 proteins, the rate of internalization of Env protein from the surfaces of HIV-1-infected cells is extremely slow. The presence of the Pr55gag precursor protein is necessary and sufficient for inhibition of Env protein internalization, while a mutant Pr55-gag that is incapable of mediating Env incorporation into virions is also unable to inhibit endocytosis of the Env protein. The failure of the Env protein to undergo endocytosis from the surface of an HIV-1-infected cell may reflect the fact that the proposed interaction of the matrix domain of the Gag protein with Env during assembly prevents the interaction of Env with host adaptin molecules that recruit plasma membrane molecules such as the transferrin receptor into clathrin-coated pits. When the normal ratio of Gag and Env proteins in the infected cells is altered by overexpression of Env protein, this mechanism allows removal of excess Env protein from the cell surface. Taken together, these results suggest that a highly conserved system to reduce surface levels of the Env protein functions to remove Env protein that is not associated with Gag and that is therefore not destined for incorporation into virions. This mechanism for the regulation of surface levels of Env protein may protect infected cells from Env-dependent cytopathic effects or Env-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794289      PMCID: PMC190695     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

Review 1.  Retrovirus envelope glycoproteins.

Authors:  E Hunter; R Swanstrom
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Cloning and characterization of human immunodeficiency virus type 1 variants diminished in the ability to induce syncytium-independent cytolysis.

Authors:  M Stevenson; S Haggerty; C Lamonica; A M Mann; C Meier; A Wasiak
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system.

Authors:  O Haffar; J Garrigues; B Travis; P Moran; J Zarling; S L Hu
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  The intracytoplasmic domain of gp41 mediates polarized budding of human immunodeficiency virus type 1 in MDCK cells.

Authors:  R Lodge; H Göttlinger; D Gabuzda; E A Cohen; G Lemay
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  The difference in gp160 and gp120 of HIV type 1 in the induction of CD4 downregulation preceding single-cell killing.

Authors:  Y Koga; K Nakamura; M Sasaki; G Kimura; K Nomoto
Journal:  Virology       Date:  1994-05-15       Impact factor: 3.616

7.  Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus.

Authors:  C C LaBranche; M M Sauter; B S Haggarty; P J Vance; J Romano; T K Hart; P J Bugelski; J A Hoxie
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix.

Authors:  E O Freed; M A Martin
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC.

Authors:  J F Rowell; P E Stanhope; R F Siliciano
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

10.  Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains.

Authors:  F Mammano; E Kondo; J Sodroski; A Bukovsky; H G Göttlinger
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  77 in total

1.  An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.

Authors:  P A Goepfert; K Shaw; G Wang; A Bansal; B H Edwards; M J Mulligan
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.

Authors:  John T West; Sally K Weldon; Stephanie Wyss; Xiaoxu Lin; Qin Yu; Markus Thali; Eric Hunter
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Semliki forest virus budding: assay, mechanisms, and cholesterol requirement.

Authors:  Y E Lu; M Kielian
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Identification of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface.

Authors:  M P Grange; V Blot; L Delamarre; I Bouchaert; A Rocca; A Dautry-Varsat; M C Dokhélar
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity.

Authors:  John R Day; Carsten Münk; John C Guatelli
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

7.  Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.

Authors:  Virginie Sandrin; Delphine Muriaux; Jean-Luc Darlix; François-Loïc Cosset
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  The Rous sarcoma virus Env glycoprotein contains a highly conserved motif homologous to tyrosine-based endocytosis signals and displays an unusual internalization phenotype.

Authors:  C Ochsenbauer; S R Dubay; E Hunter
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

9.  Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity.

Authors:  Miranda Harris; Sneha Ratnapriya; Angela Chov; Héctor Cervera; Alisha Block; Christopher Gu; Nathaniel Talledge; Louis M Mansky; Joseph Sodroski; Alon Herschhorn
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

10.  Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail.

Authors:  Melissa V Fernandez; Huxley K Hoffman; Nairi Pezeshkian; Philip R Tedbury; Schuyler B van Engelenburg; Eric O Freed
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.